Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

355
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
355
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.0K
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

241
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
241

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Synergistic fusion: An integrated pipeline of CLAHE, YOLO models, and advanced super-resolution for enhanced thermal eye detection.

PloS one·2025
Same author

End-to-End Depth-Guided Relighting Using Lightweight Deep Learning-Based Method.

Journal of imaging·2023
Same journal

Discovery of Phytochemicals as Inhibitors of Human Metapneumovirus: In-Silico Docking Studies.

Current drug discovery technologies·2026
Same journal

From Molecules to Manufacturing: Expanding Role of Artificial Intelligence in Pharmaceutical Sciences.

Current drug discovery technologies·2026
Same journal

Targeting Biofilm Formation in Acinetobacter baumannii: In Silico Discovery of Novel Candidate Inhibitors for Acyl-Homoserine Lactone Synthase.

Current drug discovery technologies·2026
Same journal

Effects of Ganoderma lucidum Polysaccharide Peptide on Inflammatory and Metabolic Biomarkers in Obese Patients with Cardiometabolic Syndrome: A Randomized Controlled Trial.

Current drug discovery technologies·2026
Same journal

Using Computational Intelligence to Connect Data and Drug Design in Medicinal Chemistry: A Review.

Current drug discovery technologies·2026
Same journal

Uncovering the Anti-Pleurisy Mechanism of Shizao Decoction via Network Pharmacology and Molecular Docking.

Current drug discovery technologies·2026
查看所有相关文章

相关实验视频

Updated: Jan 13, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.3K

用药物发现堆回归器进行元建模:一种可解释的AI视角

Spoorthi J S1, Vijayalakshmi M2, Sasithradevi A3

  • 1School of Computer Science and Engineering, Vellore Institute of Technology, 600127, Chennai, India.

Current drug discovery technologies
|October 28, 2025
PubMed
概括
此摘要是机器生成的。

可解释组合模型通过提高预测准确性和提供对化合物行为的清晰洞察来增强药物发现中的AI. 这种方法提高了人们对人工智能驱动的治疗开发的信心.

关键词:
这就是COVID-19的原因.药物发现 药物发现在 LIME 时代,这就是 SHAP SHAP 的意思.药物发现堆回归器整体方法 整体方法

更多相关视频

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

相关实验视频

Last Updated: Jan 13, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.3K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

科学领域:

  • 人工智能在药物发现中的作用
  • 计算化学的计算化学
  • 机器学习用于药理学

背景情况:

  • 药物发现受到复杂的数据集,长时间和药物向相互作用的不准确预测的挑战.
  • 这些挑战阻碍了及时的治疗开发,特别是在COVID-19等全球卫生危机期间.
  • 本研究通过整合合体机器学习与可解释的人工智能 (XAI) 来解决这些问题.

研究的目的:

  • 提高AI模型在药物发现中的预测准确度和透明度.
  • 利用整体方法和XAI进行更强大和可解释的药物向相互作用预测.
  • 为明智的分子设计提供化学上有意义的见解.

主要方法:

  • 在104个COVID-19化合物上训练了三个回归模型 (随机森林,支持向量回归,多层感知器).
  • 实施的整体策略:投票回归和堆叠回归.
  • 使用SHAP (夏普利添加式解释) 和LIME (局部可解释模型不可知解释) 进行特征重要性分析.

主要成果:

  • 药物发现堆回归模型表现出优异的性能,MSE为0.18和R2为0.88.
  • SHAP和LIME确定了EffectiveRotorCount3D和YStericQuadrupole3D作为关键的分子描述符.
  • 这些特征与分子灵活性和对药物活性至关重要的固体效应有关.

结论:

  • 将组合建模与可解释性相结合,可显著提高药物发现中的预测稳定性和可解释性.
  • SHAP和LIME的整合提供了化学相关的见解,支持合理的分子设计和增加模型透明度.
  • 可解释的组合模型提高了AI在药物发现中的可靠性和适用性,为治疗开发提供了可扩展的解决方案.